Hannah Mosher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hannah Mosher has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hallie B. Remer
University of Miami Miller School of Medicine, Miami, FL, USA
3 shared publications Chukwuemeka U. Osondu
Baptist Health Orthopedic Care, Baptist Health South Florida Coral Gables Florida USA
2 shared publicationsJuan C. Suarez
Baptist Health Orthopedic Care, Baptist Health South Florida Coral Gables Florida USA
2 shared publicationsAlexander van der Ven
Baptist Health Orthopedic Care, Baptist Health South Florida, Miami, FL, USA
1 shared publication- Andrew Eric Rosenberg
Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, Florida
1 shared publication - Aneesh V. Samineni
Department of Orthopaedic Surgery, University of Miami Hospital, Miami, FL, USA
1 shared publication
Latest Publications
- 13 April 2026
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 484 (10) , 1989-2000
Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?
Background: Osteoarticular allografts are used for knee reconstruction after tumor resection, but the number of these types of reconstruction has declined because of frequent complications and perceived better results with tumor endoprostheses. Failed osteoarticular allografts can be salvaged with megaprosthesis conversion, but it remains unclear whether the outcomes of the patients who undergo conversion differ from those of patients who have primary megaprosthesis reconstructions at the time of tumor resection. Also, there is lack of evidence on the comparison of implant survival. This study aimed to fill the gaps in our current knowledge about conversion megaprosthesis to inform patients and guide treatment accordingly. Questions/purposes: (1) Did the survivorship free from revision or amputation differ between patients who initially received an osteoarticular allograft and underwent a conversion to a megaprosthesis and patients who underwent primary megaprosthesis reconstruction? (2) Did the groups differ in terms of Musculoskeletal Tumor Society-93 (MSTS-93) scores, knee flexion angle, and extensor lag? Methods: Between January 1997 and December 2023, we treated 276 patients with megaprosthesis for bone sarcoma of the distal femur and proximal tibia, including patients who had a failed osteoarticular allograft in the distal femur or proximal tibia and were subsequently converted to megaprosthesis as well as patients who initially underwent megaprosthesis reconstruction. At our institution, initial patient selection for osteoarticular allograft reconstruction is influenced by several factors. Patients who were younger, had fewer comorbidities, and who would be more compliant with the follow-up protocol usually underwent osteoarticular allograft reconstruction for the initial resection procedure. All patients were followed up for at least 2 years after megaprosthesis reconstruction or until reoperation or death (mean ± SD follow-up time 10 ± 8 years). The patient cohort in the institutional database had 29 patients with conversion before the exclusion criteria were applied. Seven percent (2 of 29) of the patients underwent conversion with different implant systems and 14% (4 of 29) of the patients had insufficient follow-up. Seventy-nine percent (23 of 29) of the patients were eligible for final analysis. In the primary group, there were 247 patients before the exclusion criteria were applied. Twenty-one percent (52 of 247) of the patients underwent primary reconstruction with different implant systems, 6% (14 of 247) received uncemented stems, 2% (6 of 247) underwent extraarticular resection, and 1% (2 of 247) of the patients initially underwent allograft-prosthetic composite reconstruction. After the exclusion criteria were applied, 70% (173 of 247) of the patients were eligible. Of those patients, 20% (49 of 247) had insufficient follow-up. Fifty percent (124 of 247) of the patients were eligible for the final analysis. After 1:2 nearest-neighbor propensity score matching, 23 patients who underwent a conversion to endoprosthesis were compared with 46 patients who had a primary megaprosthesis implanted at the time of the tumor resection. Groups were matched for age, gender, BMI, diagnosis, tumor location, resection ratio, stem length, and stem diameter. After matching, osteosarcoma was the most common diagnosis for the conversion and primary groups (65% versus 70%, standardized mean difference [SMD] -0.09). Distal femur was the most common tumor location for the conversion and primary groups (70% versus 70%, SMD 0.00). We compared survivorship free from revision and survivorship free from amputation between patients with conversion and primary megaprostheses using competing risk analysis. Tumor recurrence and death were assessed as competing events for competing risk analysis. We then compared functional outcomes, including the MSTS-93 score, knee flexion angle, and extensor lag with the Welch t-test. Additionally, we performed a noninferiority test to evaluate whether patients with conversion had functional outcomes (MSTS-93 score, knee flexion angle, and extensor lag) not worse than the primary group with a 15% margin. In comparisons, MSTS-93 scores and knee flexion angles were regarded as clinically inferior in lower values, whereas extensor lag was regarded as clinically inferior in higher values. Results: Survivorship free from revision did not differ between the conversion and primary groups at 5 years (79% [95% confidence interval (CI) 60% to 98%] versus 75% [95% CI 61% to 90%]) and at 15 years (37% [95% CI 6% to 67%] versus 49% [95% CI 25% to 73%]; p = 0.61). Survivorship free from amputations did not differ between the conversion and primary groups at 15 years (100% [95% CI 100% to 100%] versus 92% [95% CI 81% to 100%]; p = 0.29). Likewise, the conversion and primary groups did not differ in terms of MSTS-93 scores at mean ± SD 11 ± 8 years (23 ± 4 versus 25 ± 5, mean difference 1 [95% CI -1 to 4]; p = 0.17). The conversion and primary groups did not differ in terms of knee flexion angles at 11 ± 8 years (94° ± 24° versus 104° ± 19°; p = 0.17). The conversion and primary groups did not differ in terms of extensor lag at 11 ± 8 years (3° ± 3° versus 6° ± 9°; p = 0.21). The conversion and primary groups differed in terms of extensor lag in proximal tibia replacements (5° ± 4° versus 13° ± 12°; p = 0.01). Noninferiority was demonstrated for MSTS-93 scores and extensor lag for the conversion group. Conclusion: A conversion megaprosthesis yields outcomes no different than a primary megaprosthesis in terms implant survival, limb preservation, and functional outcomes. When limb salvage is feasible, a conversion megaprosthesis represents a reliable salvage option for failed osteoarticular allograft reconstruction. Our findings show that...
- 13 April 2026
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 484 (10) , 1989-2000
Do Patients Who Undergo Conversion of Failed Osteoarticular Allografts to Megaprostheses Have Worse Outcomes Than Patients Treated With Primary Megaprostheses at Initial Resection?
Background: Osteoarticular allografts are used for knee reconstruction after tumor resection, but the number of these types of reconstruction has declined because of frequent complications and perceived better results with tumor endoprostheses. Failed osteoarticular allografts can be salvaged with megaprosthesis conversion, but it remains unclear whether the outcomes of the patients who undergo conversion differ from those of patients who have primary megaprosthesis reconstructions at the time of tumor resection. Also, there is lack of evidence on the comparison of implant survival. This study aimed to fill the gaps in our current knowledge about conversion megaprosthesis to inform patients and guide treatment accordingly. Questions/purposes: (1) Did the survivorship free from revision or amputation differ between patients who initially received an osteoarticular allograft and underwent a conversion to a megaprosthesis and patients who underwent primary megaprosthesis reconstruction? (2) Did the groups differ in terms of Musculoskeletal Tumor Society-93 (MSTS-93) scores, knee flexion angle, and extensor lag? Methods: Between January 1997 and December 2023, we treated 276 patients with megaprosthesis for bone sarcoma of the distal femur and proximal tibia, including patients who had a failed osteoarticular allograft in the distal femur or proximal tibia and were subsequently converted to megaprosthesis as well as patients who initially underwent megaprosthesis reconstruction. At our institution, initial patient selection for osteoarticular allograft reconstruction is influenced by several factors. Patients who were younger, had fewer comorbidities, and who would be more compliant with the follow-up protocol usually underwent osteoarticular allograft reconstruction for the initial resection procedure. All patients were followed up for at least 2 years after megaprosthesis reconstruction or until reoperation or death (mean ± SD follow-up time 10 ± 8 years). The patient cohort in the institutional database had 29 patients with conversion before the exclusion criteria were applied. Seven percent (2 of 29) of the patients underwent conversion with different implant systems and 14% (4 of 29) of the patients had insufficient follow-up. Seventy-nine percent (23 of 29) of the patients were eligible for final analysis. In the primary group, there were 247 patients before the exclusion criteria were applied. Twenty-one percent (52 of 247) of the patients underwent primary reconstruction with different implant systems, 6% (14 of 247) received uncemented stems, 2% (6 of 247) underwent extraarticular resection, and 1% (2 of 247) of the patients initially underwent allograft-prosthetic composite reconstruction. After the exclusion criteria were applied, 70% (173 of 247) of the patients were eligible. Of those patients, 20% (49 of 247) had insufficient follow-up. Fifty percent (124 of 247) of the patients were eligible for the final analysis. After 1:2 nearest-neighbor propensity score matching, 23 patients who underwent a conversion to endoprosthesis were compared with 46 patients who had a primary megaprosthesis implanted at the time of the tumor resection. Groups were matched for age, gender, BMI, diagnosis, tumor location, resection ratio, stem length, and stem diameter. After matching, osteosarcoma was the most common diagnosis for the conversion and primary groups (65% versus 70%, standardized mean difference [SMD] -0.09). Distal femur was the most common tumor location for the conversion and primary groups (70% versus 70%, SMD 0.00). We compared survivorship free from revision and survivorship free from amputation between patients with conversion and primary megaprostheses using competing risk analysis. Tumor recurrence and death were assessed as competing events for competing risk analysis. We then compared functional outcomes, including the MSTS-93 score, knee flexion angle, and extensor lag with the Welch t-test. Additionally, we performed a noninferiority test to evaluate whether patients with conversion had functional outcomes (MSTS-93 score, knee flexion angle, and extensor lag) not worse than the primary group with a 15% margin. In comparisons, MSTS-93 scores and knee flexion angles were regarded as clinically inferior in lower values, whereas extensor lag was regarded as clinically inferior in higher values. Results: Survivorship free from revision did not differ between the conversion and primary groups at 5 years (79% [95% confidence interval (CI) 60% to 98%] versus 75% [95% CI 61% to 90%]) and at 15 years (37% [95% CI 6% to 67%] versus 49% [95% CI 25% to 73%]; p = 0.61). Survivorship free from amputations did not differ between the conversion and primary groups at 15 years (100% [95% CI 100% to 100%] versus 92% [95% CI 81% to 100%]; p = 0.29). Likewise, the conversion and primary groups did not differ in terms of MSTS-93 scores at mean ± SD 11 ± 8 years (23 ± 4 versus 25 ± 5, mean difference 1 [95% CI -1 to 4]; p = 0.17). The conversion and primary groups did not differ in terms of knee flexion angles at 11 ± 8 years (94° ± 24° versus 104° ± 19°; p = 0.17). The conversion and primary groups did not differ in terms of extensor lag at 11 ± 8 years (3° ± 3° versus 6° ± 9°; p = 0.21). The conversion and primary groups differed in terms of extensor lag in proximal tibia replacements (5° ± 4° versus 13° ± 12°; p = 0.01). Noninferiority was demonstrated for MSTS-93 scores and extensor lag for the conversion group. Conclusion: A conversion megaprosthesis yields outcomes no different than a primary megaprosthesis in terms implant survival, limb preservation, and functional outcomes. When limb salvage is feasible, a conversion megaprosthesis represents a reliable salvage option for failed osteoarticular allograft reconstruction. Our findings show that...
- 3 February 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 75, 262-267
Accuracy and safety of acetabular cup placement in total hip arthroplasty using mixed-reality navigation: A prospective trial
- 3 February 2026
- Published by Elsevier in Journal of Orthopaedics
- Vol. 75, 262-267
Accuracy and safety of acetabular cup placement in total hip arthroplasty using mixed-reality navigation: A prospective trial
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (1)
Current Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature
Background: Diffuse tenosynovial giant cell tumor (DTGCT) is a locally aggressive benign tumor of the synovium. Patients often initially present with pain, stiffness, and swelling of the affected joint with varying levels of severity. Treatment traditionally involved surgical resection exclusively; however, this could be complicated by high disease recurrence rates. New research has introduced several targeted systemic therapies onto the market changing the treatment paradigm and necessitating a multidisciplinary treatment approach in specialized centers to optimize patient outcomes. Methods: This review synthesizes the current literature on DTGCT including its pathophysiology, classification, diagnosis, and available treatment options. There is a particular focus on the newer systemic therapies available and how these medications may be used in conjunction with surgery to enhance disease control. Results: DTGCT most commonly affects young to middle-aged adults, with a slight female predominance, and is most frequently found in the knee. Arthroscopic and even open synovectomy can have disease recurrence rates exceeding 50%. Colony stimulating factor 1 (CSF1) receptor inhibitors have proven effective at symptom palliation and reducing tumor burden in approximately 40% of patients. While these medications improve the quality of life for patients with unresectable disease, they may also be effective in the neoadjuvant setting to downstage surgical approaches and possibly improve disease control in otherwise highly morbid cases. Conclusions: Surgery alone, the traditional standard for DTGCT, is often insufficient due to high recurrence rates. Systemic therapies can restore function and improve quality of life in patients with advanced disease with rare—but potentially serious—adverse effects. Combining surgical resection with neoadjuvant CSF1R inhibition may provide superior outcomes. Further research is needed to refine the role of systemic agents and develop multidisciplinary protocols. Although initial symptoms often lead patients to community providers, optimal care for patients with DTGCT is best delivered at referral centers with dedicated musculoskeletal oncology programs. Level of Evidence: Level V . See Instructions for Authors for a complete description of levels of evidence.
- 1 January 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (1)
Open AccessCurrent Treatment Strategies for Diffuse Tenosynovial Giant Cell Tumor: A Review of the Literature
Background: Diffuse tenosynovial giant cell tumor (DTGCT) is a locally aggressive benign tumor of the synovium. Patients often initially present with pain, stiffness, and swelling of the affected joint with varying levels of severity. Treatment traditionally involved surgical resection exclusively; however, this could be complicated by high disease recurrence rates. New research has introduced several targeted systemic therapies onto the market changing the treatment paradigm and necessitating a multidisciplinary treatment approach in specialized centers to optimize patient outcomes. Methods: This review synthesizes the current literature on DTGCT including its pathophysiology, classification, diagnosis, and available treatment options. There is a particular focus on the newer systemic therapies available and how these medications may be used in conjunction with surgery to enhance disease control. Results: DTGCT most commonly affects young to middle-aged adults, with a slight female predominance, and is most frequently found in the knee. Arthroscopic and even open synovectomy can have disease recurrence rates exceeding 50%. Colony stimulating factor 1 (CSF1) receptor inhibitors have proven effective at symptom palliation and reducing tumor burden in approximately 40% of patients. While these medications improve the quality of life for patients with unresectable disease, they may also be effective in the neoadjuvant setting to downstage surgical approaches and possibly improve disease control in otherwise highly morbid cases. Conclusions: Surgery alone, the traditional standard for DTGCT, is often insufficient due to high recurrence rates. Systemic therapies can restore function and improve quality of life in patients with advanced disease with rare—but potentially serious—adverse effects. Combining surgical resection with neoadjuvant CSF1R inhibition may provide superior outcomes. Further research is needed to refine the role of systemic agents and develop multidisciplinary protocols. Although initial symptoms often lead patients to community providers, optimal care for patients with DTGCT is best delivered at referral centers with dedicated musculoskeletal oncology programs. Level of Evidence: Level V . See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 30 September 2025
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 43 (12) , 2212-2220
Can Hounsfield Unit Evaluation of Preoperative CT Scans Predict Surgeon's Preference of Cementless Fixation in Total Knee Arthroplasty?
Adequate bone quality is necessary for reliable cementless fixation during total knee arthroplasty (TKA). Hounsfield Units (HUs) can be a useful surrogate of bone density, and therefore a proxy of bone quality. We sought to determine whether HU would correlate with subjective intraoperative assessment of bone quality and hence use of cementless fixation. A retrospective review of patients who underwent a robotic‐assisted TKA between June 2022 and June 2024 by a single surgeon was conducted. HU measurements were obtained at three regions of interest (ROI) within the tibial plateau on preoperative axial‐CT scans. Patients were divided into cementless or cemented tibial implant fixation groups based upon subjective intraoperative bone quality assessment. Demographic data such as age, sex, and BMI were collected. The final cohort included 630 patients. Cementless fixation was used in 58.3% of cases. Cementless patients had a higher combined overall average HU measurement (152.7 vs. 105.6, p < 0.001). Point‐biserial correlation showed moderate inverse correlations between implant fixation type and HU measurements (all p < 0.001). ROC analysis and predictive modeling found that the best performance was derived from the combined model followed by combined demographics alone, and then HU measurements alone (AUC: 0.853 vs. 0.808 vs. 0.757). Standalone demographic resulted in the poorer predictive modeling. Ultimately, cementless fixation was associated with higher HU measurements compared to cemented fixation in all 3 ROI. HU in conjunction with combined demographic data offered the greatest confidence in predicting fixation type and therefore may be utilized to aid in decision‐making and surgical planning for TKA.
- 30 September 2025
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 43 (12) , 2212-2220
Open AccessCan Hounsfield Unit Evaluation of Preoperative CT Scans Predict Surgeon's Preference of Cementless Fixation in Total Knee Arthroplasty?
Adequate bone quality is necessary for reliable cementless fixation during total knee arthroplasty (TKA). Hounsfield Units (HUs) can be a useful surrogate of bone density, and therefore a proxy of bone quality. We sought to determine whether HU would correlate with subjective intraoperative assessment of bone quality and hence use of cementless fixation. A retrospective review of patients who underwent a robotic‐assisted TKA between June 2022 and June 2024 by a single surgeon was conducted. HU measurements were obtained at three regions of interest (ROI) within the tibial plateau on preoperative axial‐CT scans. Patients were divided into cementless or cemented tibial implant fixation groups based upon subjective intraoperative bone quality assessment. Demographic data such as age, sex, and BMI were collected. The final cohort included 630 patients. Cementless fixation was used in 58.3% of cases. Cementless patients had a higher combined overall average HU measurement (152.7 vs. 105.6, p < 0.001). Point‐biserial correlation showed moderate inverse correlations between implant fixation type and HU measurements (all p < 0.001). ROC analysis and predictive modeling found that the best performance was derived from the combined model followed by combined demographics alone, and then HU measurements alone (AUC: 0.853 vs. 0.808 vs. 0.757). Standalone demographic resulted in the poorer predictive modeling. Ultimately, cementless fixation was associated with higher HU measurements compared to cemented fixation in all 3 ROI. HU in conjunction with combined demographic data offered the greatest confidence in predicting fixation type and therefore may be utilized to aid in decision‐making and surgical planning for TKA.
- Open Access
- 4 July 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (12) , 3870-3883
Screening for Osteoporosis in Nonagenarians: A Scoping Review
Background: As the United States population continues to age and advancements contribute to enhanced life expectancy, care for nonagenarians (adults aged 90 years and older) is as important as ever. A prominent concern within healthcare for the oldest old remains the occurrence of fragility fractures, and subsequent 1‐year mortality, making prevention key. As it stands, current guidelines recommend initial screening for all patients aged 65 years or older without further guidance regarding age‐related surveillance. The purpose of this scoping review is to better understand the current literature surrounding the benefits and shortcomings of osteoporosis screening and intervention among nonagenarians. Methods: A comprehensive literature search following PRISMA guidelines was conducted using Cochrane, CINAHL, Embase, SCOPUS, Web of Science, and PubMed‐MEDLINE from 2018 to present. The search yielded 3346 studies. Results: Twenty‐one articles met inclusion criteria. Common themes were identified among included studies: evaluation of the effectiveness of existing screening guidelines, utility of new osteoporotic screening tools including fracture risk calculators, the role of frailty and multimorbidity in osteoporosis, and reporting of treatment rates and disparities in the management of osteoporosis. Conclusions: Osteoporosis screening and management has been poorly studied within the population of nonagenarians. When caring for the oldest old, there is an apparent discrepancy between current guidelines and clinical decision making. We highlight the need for future research centering on nonagenarians as the primary study group in order to establish factors which should be incorporated into future predictive models and screening recommendations.
- 4 July 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (12) , 3870-3883
Open AccessScreening for Osteoporosis in Nonagenarians: A Scoping Review
Background: As the United States population continues to age and advancements contribute to enhanced life expectancy, care for nonagenarians (adults aged 90 years and older) is as important as ever. A prominent concern within healthcare for the oldest old remains the occurrence of fragility fractures, and subsequent 1‐year mortality, making prevention key. As it stands, current guidelines recommend initial screening for all patients aged 65 years or older without further guidance regarding age‐related surveillance. The purpose of this scoping review is to better understand the current literature surrounding the benefits and shortcomings of osteoporosis screening and intervention among nonagenarians. Methods: A comprehensive literature search following PRISMA guidelines was conducted using Cochrane, CINAHL, Embase, SCOPUS, Web of Science, and PubMed‐MEDLINE from 2018 to present. The search yielded 3346 studies. Results: Twenty‐one articles met inclusion criteria. Common themes were identified among included studies: evaluation of the effectiveness of existing screening guidelines, utility of new osteoporotic screening tools including fracture risk calculators, the role of frailty and multimorbidity in osteoporosis, and reporting of treatment rates and disparities in the management of osteoporosis. Conclusions: Osteoporosis screening and management has been poorly studied within the population of nonagenarians. When caring for the oldest old, there is an apparent discrepancy between current guidelines and clinical decision making. We highlight the need for future research centering on nonagenarians as the primary study group in order to establish factors which should be incorporated into future predictive models and screening recommendations.
- Open Access
- 9 June 2025
- Published by Elsevier in Arthroplasty Today
- Vol. 33, 101737
Current Rates and Trends of Venous Thromboembolism After Total Hip and Knee Arthroplasty: An Updated Analysis Utilizing the NSQIP Database
- 9 June 2025
- Published by Elsevier in Arthroplasty Today
- Vol. 33, 101737
Open AccessCurrent Rates and Trends of Venous Thromboembolism After Total Hip and Knee Arthroplasty: An Updated Analysis Utilizing the NSQIP Database